Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010191 · ClinicalTrials.gov registry record · NA
Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)
A NA study of Irritable Bowel Syndrome, sponsored by Harvard University Faculty of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01010191: Completed NA study of Irritable Bowel Syndrome, sponsored by Harvard University Faculty of Medicine.
NCT01010191 is a NA study of Irritable Bowel Syndrome that has completed, run by Harvard University Faculty of Medicine. The registered enrollment target is 70 participants, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01010191, a NA study of Irritable Bowel Syndrome, has completed, sponsored by Harvard University Faculty of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Irritable bowel syndrome patients will be given either placebo pill or no treatment for a period of 3 weeks.
Conditions Studied
Interventions
- OTHER Sugar pill
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-04 |
| Phase | NA |
What the finished NCT01010191 record still lists
NCT01010191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Sugar pill is the first listed.
NCT01010191 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01010191 about?
NCT01010191 is a clinical study titled "Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)". Irritable bowel syndrome patients will be given either placebo pill or no treatment for a period of 3 weeks.
What is the current status of trial NCT01010191?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2008-07. Estimated completion is 2010-04.
What conditions does trial NCT01010191 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01010191?
The interventions under investigation include: Sugar pill (OTHER).
Who is sponsoring clinical trial NCT01010191?
This trial is sponsored by Harvard University Faculty of Medicine, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01010191 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01010191's enrollment target sits among peer trials
70 28th of 47 higher than 19 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia